• Stefan Verheye, John A Ormiston, James Stewart, Mark Webster, Elias Sanidas, Ricardo Costa, J Ribamar Costa, Daniel Chamie, Andrea S Abizaid, Ibraim Pinto, Lynn Morrison, Sara Toyloy, Vinayak Bhat, John Yan, and Alexandre Abizaid.
• Antwerp Cardiovascular Center, ZNA Middelheim, Antwerp, Belgium. Electronic address: stefan.verheye@gmail.com.
• JACC Cardiovasc Interv. 2014 Jan 1;7(1):89-99.

ObjectivesThis study sought to perform clinical and imaging assessments of the DESolve Bioresorbable Coronary Scaffold (BCS).BackgroundBCS, which is drug eluting, may have potential advantages compared with conventional metallic drug-eluting stents. The DESolve system, designed to provide vessel support and neointimal suppression, combines a poly-l-lactic acid-based scaffold with the antiproliferative myolimus.MethodsThe DESolve First-in-Man (a non-randomized, consecutive enrollment evaluation of the DESolve myolimus eluting bioresorbable coronary stent in the treatment of patients with de novo native coronary artery lesions) trial was a prospective multicenter study enrolling 16 patients eligible for treatment. The principal safety endpoint was a composite of cardiac death, myocardial infarction, and clinically indicated target lesion revascularization. The principal imaging endpoint was in-scaffold late lumen loss (LLL) assessed by quantitative coronary angiography (QCA) at 6 months. Intravascular ultrasound (IVUS) and optical coherence tomography (OCT) imaging was performed at baseline and 6 months; multislice computed tomography (MSCT) was performed at 12 months.ResultsAcute procedural success was achieved in 15 of 15 patients receiving a study scaffold. At 12 months, there was no scaffold thrombosis and no major adverse cardiac events directly attributable to the scaffold. At 6 months, in-scaffold LLL (by QCA) was 0.19 ± 0.19 mm; neointimal volume (by IVUS) was 7.19 ± 3.56%, with no evidence of scaffold recoil or late malapposition. Findings were confirmed with OCT and showed uniform, thin neointimal coverage (0.12 ± 0.04 mm). At 12 months, MSCT demonstrated excellent vessel patency.ConclusionsThis study demonstrated the feasibility and efficacy of the DESolve BCS. Results showing low in-scaffold LLL, low % neointimal volume at 6 months, no chronic recoil, and maintenance of lumen patency at 12 months prompt further study. (DESolve First-in-Man; EudraCT number 2011-000027-32).Copyright © 2014 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

76 keywords...

hide…